+ All Categories
Home > Technology > Why test blend uniformity

Why test blend uniformity

Date post: 02-Jul-2015
Category:
Upload: bhavesh-sondagar
View: 7,116 times
Download: 2 times
Share this document with a friend
Description:
Background to the work of the BUWGGarth Boehm BUWG Draft RecommendationsTom Garcia Data Mining: Challenging the TheoryTom Garcia
51
PQR I Introduction Background to the work of the BUWG Garth Boehm BUWG Draft Recommendations Tom Garcia Data Mining: Challenging the Theory Tom Garcia
Transcript
Page 1: Why test blend uniformity

PQR

IIntroduction

Background to the work of the BUWG

Garth Boehm

BUWG Draft Recommendations

Tom Garcia

Data Mining: Challenging the Theory

Tom Garcia

Page 2: Why test blend uniformity

PQR

IWhy Test Blend Uniformity?

21CFR211.110

(a) To assure batch uniformity and integrity of drug products, written procedures shall be established and followed that describe the in-process controls, tests, or examinations to be conducted on appropriate samples of in-process materials of each batch. ……..

(3) Adequacy of mixing to assure uniformity and homogeneity; …...

Page 3: Why test blend uniformity

PQR

IWhy Test Blend Uniformity?

OGD’s Draft Guidance

• All Solid Dosage forms <50% active or <50 mg require routine BUA

• Use 6 to 10 samples, 1 - 3 unit weights

• Must meet mean 90.0% to 110.0% label claim, RSD NMT 5.0%

Page 4: Why test blend uniformity

PQR

IProduct Quality Research Institute

• PQRI (www.pqri.org) is a collaborative effort between FDA, Industry, and Academia.

• PQRI’s mission is to provide a scientific basis for developing Regulatory Policy.

• One of PQRI’s initiatives is to set up ‘expert’ Working Groups to analyze particular areas and make recommendations on future Regulatory Policy.

Page 5: Why test blend uniformity

PQR

IBlend Uniformity Working Group

• The Blend Uniformity Working Group was established in late 1999

• The group is chaired by Tom Garcia and has members from academia, FDA (CDER and DMPQ), and industry (innovator and generic).

• The group is charged with making scientifically based recommendations on suitable procedures for assuring batch homogeneity.

Page 6: Why test blend uniformity

PQR

IBUWG Actions

• Conducted Industry Practices Survey

• Published Uniformity Troubleshooting Guide

• Held Public Workshop on BU testing issues

• Held several Working Group meetings

• Written Draft Proposal for use of Stratified Testing of Dosage Units

• Sought data to challenge proposed method

Page 7: Why test blend uniformity

PQR

IIndustry Practices Survey

• Survey was blinded to assure confidentiality

• Sent to all solid dose sponsors with at least one approved NDA or ANDA that could be located

• Designed to elicit information on general practices regarding BU sampling and testing

Page 8: Why test blend uniformity

PQR

IIndustry Practices Survey

• 28 of 134 replied (20%), mostly large manufacturers

• Survey asked questions on Demographics, Sampling, Routine Testing, Validation Testing, Cause of Failure, Cost, & New Technology

• Full Survey and Results can be found at www.pqri.org and a summary in August 2001 Pharmaceutical Technology

Page 9: Why test blend uniformity

PQR

IIndustry Practices Survey

• The picture that emerged was of a conservative industry that:

• Samples with conventional sampling thieves taking 1 - 3 unit dose sample sizes

• Tests samples with conventional ‘wet’ analytical methods

• Uses established acceptance criteria

Page 10: Why test blend uniformity

PQR

IIndustry Practices Survey

• About 2/3 for routine batches and 1/2 for validation batches are prepared to defeat failing BU results with enhanced testing

• Have trouble with 10% to 20% of products

• Think failures are due to sampling or analytical error

• Have not adopted any ‘new technology’

Page 11: Why test blend uniformity

PQR

ITroubleshooting Guide

• Early in the BUWG discussions it became apparent that no concise guide was available for diagnosing blend or dosage unit uniformity problems

• Jim Prescott and Tom Garcia took on the task of writing the guide and designing a companion chart

• Published in March 2001 Pharmaceutical Technology

Page 12: Why test blend uniformity

PQR

IPublic Workshop

• Based around the theme “Is BU Testing a Value Added Test?”

• Held September 2000, about 200 people attended

• Several formal presentations on aspects of blending, blend sampling, acceptance criteria, new technology, BUWG progress

• Summary published in September 2001 Pharm Tech

Page 13: Why test blend uniformity

PQR

IPublic Workshop

Presentations based around the following:

• Blending of solids is a poorly understood process

• Very difficult to sample powder bed with conventional sampling thieves

• Sampling errors are common & occur both ways

• Post-blending segregation can be a serious problem

Page 14: Why test blend uniformity

PQR

IPublic Workshop

Major part involved break-out sessions to elicit feedback from attendees.

• Is Blend Uniformity Testing on every batch a value-added test?

• How do you validate a process when you have a sampling problem?

• What new technologies are available to assess blend uniformity?

Page 15: Why test blend uniformity

PQR

IPublic Workshop

Conclusions

• Blend Uniformity Testing on every batch is not a value-added test

• Appropriate and meaningful BU testing should be conducted during development and validation

• Higher costs are acceptable if they yield meaningful data

Page 16: Why test blend uniformity

PQR

IDesired Attributes of a BUWG Recommendation

BUWG Draft Proposal

“The Use of Stratified Testing of Blend and Dosage Units to demonstrate Adequacy of Mix for Powder Blends”

1. The test should be simple to perform, maximizing the use of data

2. Acceptance criteria should be easy to evaluate and interpret

3. Acceptance criteria should demonstrate when lack of homogeneity is suspected

Page 17: Why test blend uniformity

PQR

I

PQRI BUWG Recommendation for the Use of Stratified Sampling to

Demonstrate Blend & Dosage Unit Content Uniformity

Page 18: Why test blend uniformity

PQR

IPQRI BUWG Recommendation

• Utilizes stratified sampling

• Collectively considers the uniformity of the powder blends and dosage units.

• Acknowledges that the best way to assess blend uniformity may be indirectly by measuring the uniformity of the dosage units.

Page 19: Why test blend uniformity

PQR

IScope of Recommendation

Applies to:• Process validation and

marketed batches for solid oral drug products.

• Products where the active ingredients are introduced into the blend.

Does not apply to:• Drug products where

the determination of dosage-form uniformity by weight variation is allowed.

Page 20: Why test blend uniformity

PQR

IStratified Sampling

• “The process of selecting units deliberately from various locations within a lot or batch or from various phases or periods of a process to obtain a sample.” [Glossary and Tables for Statistical Quality Control , ASQC Quality Press, copyright 1983.]

• Stratified sampling of the blend and dosage units specifically targets locations either in the blender or throughout the compression/filling operation which have a higher risk of producing failing content uniformity results.

Page 21: Why test blend uniformity

PQR

IStratified Sampling of Dosage Units

Advantages• More accurate & relevant• Eliminates blend sampling

errors• Detects segregation

following blending • Eliminates issues related to

blend sampling of toxic or potent drugs (operator safety)

Disadvantages• “Too late”

• Batch compressed/filled

• Not consistent with “quality by design”• Parametric release

• Note: Control vs. Test• BUA is utilized as a test

Page 22: Why test blend uniformity

PQR

IProcess Development

• Stratified sampling plan is not a substitution for poor process development

• Sampling technique should be defined during process development– Determine appropriate sampling device– Identify an acceptable sampling plan (for both blend and

dosage units)

• Recommendation allows blend sample sizes > 1-3X, if they can be scientifically justified

Page 23: Why test blend uniformity

PQR

I

Validation Approach

Page 24: Why test blend uniformity

PQR

IProcess Validation

Blend: 10 locations 3 samples per locationAssay 1 sample per location

Acceptance Criteria:RSD ≤ 5.0%

All individuals within +/- 10% of mean

Assay 2nd and 3rd blend samples from each location

Proceed to Stage 1Dosage Unit Testing

Mixing problemidentified

FailPass

Proceed to Stage 2Dosage Unit Testing

Yes No

Blend is not uniform.Go back to development

Investigation points to sampling bias or some other attributable cause

Page 25: Why test blend uniformity

PQR

IProcess Validation

During compression/filling,sample from at least

20 locations, taking at least 7 dosage units per location

Assay at least 3 dosageunits per location

Acceptance Criteria: RSD of all individuals ≤ 6.0%Each location mean within 90-110% target potency

All individual within 75-125% target potency

ProcessValidated

Assay at least 4 additional dosage units per location

Acceptance Criteria: RSD of all individuals ≤ 6.0%Each location mean within 90-110% target potency

All individual within 75-125% target potency

Fail

Pass

Pass

Fail

Blend is not uniform or post-blendingpractices cause segregation

Page 26: Why test blend uniformity

PQR

IJustification of Blend Sample Sizes

and Acceptance Criteria

• Number of Sampling Locations– At least 10 locations should be used for tumbling

mixers to adequately map blender

– At least 20 locations should be used for convection mixers, which are more likely to have dead spots

• Replicates Per Location– At least 3 samples/location required to perform

component variance analysis to detect the presence of sampling error

Page 27: Why test blend uniformity

PQR

IJustification of Dosage Unit Sample

Sizes and Acceptance Criteria

• Number of dosage unit samples and sample size through the use of OC curves, considering:– Weight variability

– Assay variability

– Between location error

– Within location error

• USP Content Uniformity Test used as a reference for comparison

Page 28: Why test blend uniformity

PQR

I

Figure 1 - No Between-Location VariabilityPopulation Mean = 100%, Wt. RSD = 1.5%

Within-Location RSD Varies from 1 - 10%

Total RSD, %

0 1 2 3 4 5 6 7 8 9 10 11 12

Pro

bab

ility

of

Mee

ting

Cri

teria

, %

0

20

40

60

80

100

120

20x3, 7USP

Page 29: Why test blend uniformity

PQR

I

Figure 2 - Between Location Variability ExistsPopulation Mean = 100%, Assay RSD = 1.5%, Wt. RSD = 1.5%

Between Location RSD varies from 1 - 10%

Total RSD, %

0 1 2 3 4 5 6 7 8 9 10 11 12

Pro

ba

bili

ty o

f M

ee

ting

Cri

teri

a,

%

0

20

40

60

80

100

120

20x3, 7USP

Page 30: Why test blend uniformity

PQR

IJustification of Dosage Unit

Acceptance Criteria

• RSD ≤ 6.0%– Consistent with Stage 1 USP Test

• All location means 90-110% target potency – Detects drifting/segregation or non-uniform spots in

the blend

• All individuals within 75-125% target potency– Will pick up outliers, such as subpotent or

superpotent (agglomeration) dosage units

Page 31: Why test blend uniformity

PQR

IJustification of Dosage Unit

Acceptance Criteria

• Two stage test is consistent with USP Content Uniformity Test– Stage 1 and Stage 2 criteria are the same

– Stage 2 test offers a second opportunity to comply with acceptance criteria, for those batches which barely fail Stage 1 testing

Page 32: Why test blend uniformity

PQR

I

Routine Manufacture

Page 33: Why test blend uniformity

PQR

IMerging the cGMP Requirement with

Compendial Release Testing• Dosage units to be tested are in-process samples• Perform two calculations on a single set of data

– cGMP Compliance - Normalize for weight– Compendial Testing - No weight correction

• Acceptance criteria the same as that described in the USP Content Uniformity Test

• If the in-process sample is not the finished dosage form, you must demonstrate during validation that the in-process results provide the same or better control as the content uniformity data generated during compendial release testing

of the corresponding finished dosage units.

Page 34: Why test blend uniformity

PQR

IDefinition of “Readily Complies” and Impact on Degree of Testing Required

• “Readily Comply” is demonstrated if for each ANDA exhibit and/or validation batch:– RSD ≤ 4.0%, all mean results within 90.0 – 110.0%, all

individual results between 75.0 – 125.0%– Stage 1 testing allowed (10 dosage units)

• Testing for products that do not “readily comply”– Stage 2 testing (30 dosage units) for at least 5 batches– If after testing 5 consecutive batches, the criteria for the

mean is met and the RSD routinely is ≤ 5.0%, then Stage 1 testing is allowed

Page 35: Why test blend uniformity

PQR

IRoutine Manufacture

For ANDA exhibit and/or validation batches:RSD ≤ 4.0%, all mean results

90-110%, all values between 75-125%

Yes [“Readily Complies”] No [Does not “Readily Comply”]

Stage 1: Test 1 sample/locationmean 90-110%, RSD ≤ 5.0%

Stage 2: Test 3 samples/locationmean 90-110%, RSD ≤ 6.0%

No

Yes Yes

Adequacy of mix demonstrated;perform 2nd calculation to satisfy compendial release requirements

No

Adequacy of mixnot demonstrated

After passing 5Consecutive Batches

Adequacy of mix demonstrated;perform 2nd calculation to satisfy compendial release requirements

Futurelots

Page 36: Why test blend uniformity

PQR

IJustification of cGMP Compliance

Sample Sizes and Acceptance Criteria

• Sample Size: At least 10 locations, 3 dosage units per location– Consistent with the USP Content Uniformity Test

• cGMP Acceptance Criteria: RSD ≤ 5.0% and mean of all samples between 90-110% target potency– Consistent with FDA Validation Acceptance Criteria

for demonstrating adequacy of mix for powder blends

Page 37: Why test blend uniformity

PQR

IAlternative Approaches

• BUWG recommendation is one approach for evaluation of adequacy of mix

• The cGMP requirements are open to other approaches– On-line monitoring techniques such as NIR– PDA 25 approach– Traditional methods (direct sampling/analysis of

blend sample)

Page 38: Why test blend uniformity

PQR

I

Results of PQRI Datamining Effort

Page 39: Why test blend uniformity

PQR

IObjectives of Datamining Effort

• Test the hypothesis “blend uniformity is not value added testing”

• Test the assumption that means are normally distributed– Validate the use of computer simulated data

• Subject batches to PQRI, OGD, FDA Validation, PDA 25, USP, and modified USP (ICH) acceptance criteria

Page 40: Why test blend uniformity

PQR

ISummary of Data Analyzed

• Desired Categories of Data• Active ingredient < 5% and between 15-25%• Product made using direct compression and

granulation processes (either wet or dry)• Data for tablets and capsules• Commercial batches both small (50-100 kg)

and large (>400 kg)

• 8 companies submitted 149 batches

Page 41: Why test blend uniformity

PQR

ICharacteristics of Submitted Data

• Dosage Form– Tablets: 149

– Capsules: 0

• Manufacturing Process– Direct Comp: 12

– Wet Granulation: 67

– Dry Granulation: 70

Page 42: Why test blend uniformity

PQR

ITest for Normality of Means

• Tested both location and within location means for normality using the Wilk-Shapiro test for normality– Location: ~ 11% of batches had at least 1 value that

was statistically different• Most were at beginning/end of run

– Within Location: ~15% of batches had at least 1 value that was statistically different

• Conclusion: Computer simulations to estimate criteria rejection rates yield slightly smaller values (conservative) than reject rates based on actual data

Page 43: Why test blend uniformity

PQR

IComparison of Blend and Dosage

Unit Content Uniformity Data• Primary means to test they hypothesis “blend

uniformity testing is not value added”

• Plots prepared comparing dosage unit RSD as a function of blend RSD– Break the curve down into 3 zones:

• Blend RSD <3%• Blend RSD 3-5%• Blend RSD > 5%

Page 44: Why test blend uniformity

PQR

IComparison of Blend and

Dosage Form RSDs

Page 45: Why test blend uniformity

PQR

IBlend RSD < 3%

Page 46: Why test blend uniformity

PQR

IBlend RSD 3-5%

Page 47: Why test blend uniformity

PQR

IBlend RSD >5%

Page 48: Why test blend uniformity

PQR

ICorrelation Between Blend and

Dosage Unit RSD• Blend RSD < 3%: Blend data is predictive of

final dosage form uniformity– Dosage form RSD often higher (weight variability,

segregation?)

• Blend RSD 3-5%: Diminished correlation between blend data & dosage form uniformity

• Blend RSD >5%: Blend data is not predictive of content uniformity of the final dosage form

Page 49: Why test blend uniformity

PQR

IComparison of Acceptance

Criteria Criteria

PQRI ValidationResults

131/149 (88%)OGDFDA Validation

136/149 (91%)123/149 (83%)

PQRI RoutineUSP

86/88 (98%)85/88 (97%)

Revised USP (ICH)PDA 25

86/88 (98%)62/88 (70%)

Page 50: Why test blend uniformity

PQR

IDatamining Results:

“Readily” vs. “Marginally” Comply

• 83/88 (94%) passed PQRI Validation acceptance criteria

• Of the batches that met PQRI Validation acceptance criteria– Readily Comply: 79/83– Marginally Comply: 4/83

Page 51: Why test blend uniformity

PQR

IAcknowledgements

• Jerry Planchard (Aventis)• Garth Boehm (Purepac)• Joep Timmermans (Merck)• Jerry Mergen (McNeil)• Fernando Muzzio (Rutgers)

• Jean-Marie Geoffroy (Abbott)

• Jim Prescott (Jenike & Johanson)

• Pedro Jimenez (Lilly)• John Dietrick (FDA)• Jon Clark (FDA)• Neeru Takiar (FDA)

• Muralidhara Gavini (FDA)• Laura Foust (Lilly)


Recommended